Fish oil-derived n-3 polyunsaturated fatty acids for the prevention and treatment of sarcopenia
Related Experiment Video
Updated: Feb 17, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
Stuart R Gray1, Bettina Mittendorfer2
1Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Center, University of Glasgow, Glasgow, Scotland, UK.
Purpose Of Review:
Muscle mass and function decline progressively starting in middle age, which can result in sarcopenia and affect people's mobility and independence later in life. Exercise training and increased protein intake are typically recommended to counteract the age-associated decline in muscle mass and function. However, few people comply with exercise recommendations and the effectiveness of high-protein intake to halt the decline in muscle mass and function has not been proven. This review aims to explore recent developments in the potential for fish-oil derived n-3 polyunsaturated fatty acids (n-3 PUFA) to improve muscle mass and function in older people.
Recent Findings:
The results from several recent studies demonstrate that dietary supplementation with fish oil-derived n-3 PUFA stimulates muscle protein synthesis and improves muscle mass and function in sedentary older adults and augments the resistance exercise training-induced increase in muscle strength in older adults. The exact mechanisms by which fish oil-derived n-3 PUFAs exert their beneficial effects on muscle mass and function remain to be elucidated.
Summary:
Fish-oil supplementation has antisarcopenic effects and should be considered in the clinical care of older adults.
More Related Videos
14:39Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
07:25Lipid Supplementation for Longevity and Gene Transcriptional Analysis in Caenorhabditis elegans
Published on: December 9, 2022
Related Concept Videos
Atherosclerosis III: Management
Structure of Lipids